Literature DB >> 31953667

Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity.

Cesare Gagliardo1, Stefano Radellini2, Raffaella Morreale Bubella2, Giorgia Falanga1, Pierina Richiusa2, Maria Vadalà3, Alessandro Ciresi2, Massimo Midiri1, Carla Giordano4.   

Abstract

BACKGROUND: Lacrimal gland (LG) involvement in patients with Graves ophthalmopathy (GO) has been considered as a potential cause of the associated GO symptoms and different studies demonstrated the LG involvement in patients with GO than healthy controls. The aim of this study was to evaluate LG involvement, through measurement of its herniation, using a magnetic resonance imaging (MRI) index, in patients with different GO activities.
METHODS: Thirty-two consecutive Caucasian patients affected by GO were enrolled and grouped in group A (16 with inactive GO, CAS < 3) and B (16 with active GO, CAS ≥ 3) according to their GO activity. All patients underwent clinical-endocrinological assessment, a complete ocular evaluation, and orbital MRI examination.
RESULTS: No difference was found between the hormonal parameters, thyroid ultrasound-derived parameters, and thyroid-stimulating hormone (TSH) receptor (TSH-R) antibodies (TRAb) levels in group B and those in group A. The LG herniation (LGH) measurement evaluated by MRI was significantly higher in group B for both right (10.1 (7.3-17) vs. 7 (0-3.4) mm; p = 0.004) and left (8.5 (6.6-13) vs. 5.8 (0-12) mm; p = 0.026) eye than group A. A positive correlation was found between TRAb and LGH herniation (Rho 0.462, p = 0.009).
CONCLUSIONS: Measurement of LGH seems to be a good marker of the disease and GO activity. KEY POINTS: • Lacrimal gland herniation is a simple index related to disease activity • Lacrimal gland herniation is correlated to TRAb levels • Lacrimal gland evaluation could be useful to differentiate active from inactive Graves ophthalmopathy in an early stage of disease.

Entities:  

Keywords:  Graves ophthalmopathy; Lacrimal apparatus; Magnetic resonance imaging; Orbital diseases

Mesh:

Year:  2020        PMID: 31953667     DOI: 10.1007/s00330-019-06570-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  10 in total

1.  CT dimensions of the lacrimal gland in Graves orbitopathy.

Authors:  Matheson A Harris; Tony Realini; Jeffrey P Hogg; Jennifer A Sivak-Callcott
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2012 Jan-Feb       Impact factor: 1.746

Review 2.  Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis.

Authors:  Hadas Stiebel-Kalish; Eyal Robenshtok; Murat Hasanreisoglu; David Ezrachi; Ilan Shimon; Leonard Leibovici
Journal:  J Clin Endocrinol Metab       Date:  2009-06-02       Impact factor: 5.958

Review 3.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 4.  Imaging Investigation of Thyroid Eye Disease.

Authors:  Loizos C Siakallis; Jimmy M Uddin; Katherine A Miszkiel
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2018 Jul/Aug       Impact factor: 1.746

5.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

6.  Calculated computed tomography volumes of lacrimal glands and comparison to clinical findings in patients with thyroid eye disease.

Authors:  Chad M Bingham; Matheson A Harris; Tony Realini; John Nguyen; Jeffery P Hogg; Jennifer A Sivak-Callcott
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2014 Mar-Apr       Impact factor: 1.746

Review 7.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

8.  Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies.

Authors:  Anja K Eckstein; Andreas Finkenrath; Arnd Heiligenhaus; Katrin Renzing-Köhler; Joachim Esser; Carsten Krüger; Beate Quadbeck; Klaus-Peter Steuhl; Robert K Gieseler
Journal:  Acta Ophthalmol Scand       Date:  2004-06

9.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

10.  Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.

Authors:  P Perros; L Hegedüs; L Bartalena; C Marcocci; G J Kahaly; L Baldeschi; M Salvi; J H Lazarus; A Eckstein; S Pitz; K Boboridis; P Anagnostis; G Ayvaz; A Boschi; T H Brix; N Currò; O Konuk; M Marinò; A L Mitchell; B Stankovic; F B Törüner; G von Arx; M Zarković; W M Wiersinga
Journal:  Orphanet J Rare Dis       Date:  2017-04-20       Impact factor: 4.123

  10 in total
  9 in total

1.  Dixon-T2WI magnetic resonance imaging at 3 tesla outperforms conventional imaging for thyroid eye disease.

Authors:  Alexis Ollitrault; Frédérique Charbonneau; Marie-Laure Herdan; Olivier Bergès; Kevin Zuber; Lama Giovansili; Pauline Launay; Julien Savatovsky; Augustin Lecler
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

2.  Expanding diagnostic tools for dysthyroid optic neuropathy: how quantitative MRI can be used to visualize and measure orbital inflammation.

Authors:  Augustin Lecler
Journal:  Eur Radiol       Date:  2021-07-31       Impact factor: 5.315

3.  Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues.

Authors:  Hao Hu; Xiao-Quan Xu; Lu Chen; Wen Chen; Qian Wu; Huan-Huan Chen; Hui Zhu; Hai-Bin Shi; Fei-Yun Wu
Journal:  Endocrine       Date:  2020-06-05       Impact factor: 3.633

4.  A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.

Authors:  Stephanie Hiu Ling Poon; Janice Jing-Chee Cheung; Kendrick Co Shih; Yau Kei Chan
Journal:  Rev Endocr Metab Disord       Date:  2022-01-23       Impact factor: 6.514

5.  Usefulness of readout-segmented EPI-based diffusion tensor imaging of lacrimal gland for detection and disease staging in thyroid-associated ophthalmopathy.

Authors:  Lu Chen; Hao Hu; Wen Chen; Qian Wu; Jiang Zhou; Huan-Huan Chen; Xiao-Quan Xu; Hai-Bin Shi; Fei-Yun Wu
Journal:  BMC Ophthalmol       Date:  2021-07-20       Impact factor: 2.209

6.  Correlation between extent of lacrimal gland prolapse and clinical features of thyroid-associated ophthalmopathy: a retrospective observational study.

Authors:  Yang Gao; Qinglin Chang; Yang Li; Hanqiao Zhang; Zhijia Hou; Zheng Zhang; Zheng Li; Dongmei Li
Journal:  BMC Ophthalmol       Date:  2022-02-10       Impact factor: 2.209

7.  The value of SPECT/CT imaging of lacrimal glands as a means of assessing the activity of Graves' orbitopathy.

Authors:  Ru-Xuan Zhao; Ting-Ting Shi; Sha Luo; Yun-Fu Liu; Zhong Xin; Jin-Kui Yang
Journal:  Endocr Connect       Date:  2022-02-09       Impact factor: 3.335

8.  Imaging of the medial rectus muscle predicts the development of optic neuropathy in thyroid eye disease.

Authors:  Marcel Berger; Juliane Matlach; Susanne Pitz; Manfred Berres; Franz Axmacher; George J Kahaly; Marc A Brockmann; Matthias Müller-Eschner
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

9.  Current insights of applying MRI in Graves' ophthalmopathy.

Authors:  Cheng Song; Yaosheng Luo; Genfeng Yu; Haixiong Chen; Jie Shen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.